Ryan Barbara 4

What Happened Ryan Barbara, a director of Indivior Pharmaceuticals, acquired 31 shares in an open-market purchase on March 9, 2026 at $32.56 per share, a transaction valued at approximately $1,009. This was a purchase (a buy), which some investors view as a modest bullish signal from an insider, though the dollar amount is small.

Key Details

• Transaction date and price: March 9, 2026 — 31 shares at $32.56 each.
• Total value: roughly $1,009.
• Shares owned after transaction: not reported in the provided filing excerpt.
• Footnotes/plan info: no 10b5-1 plan, tax withholding, or other special footnotes disclosed in the supplied details.
• Filing timeliness: Form 4 was filed March 11, 2026 (two days after the trade), which appears to be within the SEC’s standard two-business-day reporting window.

Context This was a straightforward purchase (SEC code P). The size of the purchase is small relative to typical executive trades, so while it shows an insider buying, it does not by itself indicate a material change in insider conviction. Retail investors should weigh this alongside other insider activity, company fundamentals, and broader market factors.